Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Technology and Financials sectors led shares higher. At the close in NYSE,...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the FDA has granted Breakthrough Therapy designation to its leukemia drug Tibsovo (ivosidenib) for the treatment of...
Geron Corporation’s (NASDAQ:GERN) shares have surged 40% so far this year compared with the industry’s growth of 5.2%, riding on the progress of its sole pipeline...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 200.09 | 202.07 | 196.25 | +4.90 | +2.51% | 17.89M | NYSE | |||
| 2,697.10 | 2,706.70 | 2,675.90 | +2.6 | +0.10% | 1.08M | NASDAQ | |||
| 351.95 | 359.40 | 350.74 | -4.35 | -1.22% | 13.18M | NASDAQ | |||
| 28.98 | 30.29 | 28.81 | -0.21 | -0.72% | 3.00M | NASDAQ | |||
| 197.50 | 199.61 | 193.61 | +2.51 | +1.29% | 21.74M | NASDAQ | |||
| 121.37 | 122.04 | 120.32 | +1.12 | +0.93% | 656.40K | NYSE | |||
| 53.68 | 54.47 | 53.53 | -0.04 | -0.07% | 18.10M | NASDAQ | |||
| 204.30 | 211.46 | 203.79 | -1.16 | -0.56% | 326.26K | NYSE | |||
| 151.17 | 154.45 | 151.07 | -0.61 | -0.40% | 10.20M | NYSE | |||
| 29.92 | 31.79 | 29.92 | -1.31 | -4.19% | 4.83M | NYSE | |||
| 26.62 | 27.57 | 26.57 | -0.66 | -2.42% | 11.01M | NASDAQ | |||
| 23.36 | 23.83 | 22.97 | -0.29 | -1.23% | 5.07M | NYSE | |||
| 235.40 | 240.38 | 233.80 | -1.18 | -0.50% | 2.15M | NASDAQ | |||
| 99.85 | 100.66 | 99.52 | +0.09 | +0.09% | 748.55K | NYSE | |||
| 56.88 | 57.24 | 56.71 | -0.15 | -0.26% | 9.78M | NYSE |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.
